Complex Exploratory Study of Alcohol-Associated Hepatitis

Launched by PAVOL JOZEF SAFARIK UNIVERSITY · Apr 6, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on studying alcohol-associated hepatitis, a serious liver condition that can occur in people who consume significant amounts of alcohol. It is an important health issue because this condition is linked to high rates of death and currently lacks effective long-term treatments. The study aims to gather more information about the disease and how it affects people, as well as to identify better ways to treat it. Since current treatments, like corticosteroids, only help some patients and only for a short time, researchers hope this study will lead to better options in the future.

To participate in the trial, individuals must be at least 18 years old and have been diagnosed with alcohol-associated hepatitis, which means their liver has been injured due to alcohol use. However, those who have other serious health issues, such as certain types of cancer, or those who decide not to participate will not be eligible. Participants will need to give their consent to be part of this study, and once involved, they can expect to help researchers understand this condition better, which could ultimately lead to improved treatments for many others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Patients older than 18 years with acute liver injury / acute liver failure with later confirmation of the AH diagnosis according to the NIAAA diagnostic criteria \[14\] who provided written informed consents for admission and further differentiation, and for study participation
• Exclusion Criteria:
• • Patients not confirmed to have alcohol-associated hepatitis
• • Patients with malignancies (specifically those with life-expectancy limitation)
• • Patients who withdrew consent for study participation